

July 27, 2015

Press Release

Mitsubishi Tanabe Pharma Corporation

Organizational Restructuring

Osaka, Japan, July 27, 2015 - Mitsubishi Tanabe Pharma Corporation (President & Representative Director, CEO: Masayuki Mitsuka) announced today the following organizational restructuring.

1. Restructuring of divisions (Effective October 1, 2015)

- Research Division, Development Division, Pharmacovigilance & Quality Assurance Division and Part of the functions of Sales & Marketing Division will be reorganized into the newly-established *Sohyaku*. Innovative Research Division and *Ikuyaku*. Integrated Value Development Division.

Sohyaku. Innovative Research Division:

For the stage from basic research to the early phase of development to ensure that Proof of Concept (POC) as rapidly as possible.

Ikuyaku. Integrated Value Development Division:

For the later phase of development after acquisition of POC and preparations for product launch, as well as maximization the value of a new drug after product launch.

2. Corporate Division

(Effective August 1, 2015)

- R&D Transformation Department will be abolished.

(Effective October 1, 2015)

- Global Product Strategy Department will be abolished and its functions will be transferred to Sohyaku. Innovative Research Division and Ikuyaku. Integrated Value Development Division.
- Medical Affairs Department will be abolished and its functions will be transferred to Ikuyaku. Integrated Value Development Division.
- Medical Intelligence Department will be transferred to Ikuyaku. Integrated Value Development Division.
- External Affairs Department will be newly established.
- CEO Office will be abolished and restructured into a group-level organization.

3. Sohyaku. Innovative Research Division (Effective October 1, 2015)

- The position of Deputy Division Manager to support the Division Manager will be newly established.
- Sohyaku Strategy & Planning Department, Sohyaku Administration Department, Project Facilitation Department, Translational Research Department, Sohyaku Quality Assurance Department, Sohyaku Regulatory Affairs Department and Research Coordination Department will be newly established. The functions of Research Strategy & Planning Department, Research coordination & Administration Department, Development Planning & Coordination Department, Clinical Quality Assurance Department and Development Regulatory Affairs Department, and part of the functions of Global Product Strategy Department will be transferred to the above newly-established divisions and will be reorganized.
- Research Core Unit will be abolished. Chemistry Research Laboratories, Biology Research Laboratories, DMPK Research Laboratories and Safety Research Laboratories will be restructured to come under the direct supervision of Sohyaku. Innovative Research Division.
- Clinical Pharmacology Department will be abolished. Its functions will be transferred to Data Science Department and DMPK Research Laboratories.
- The department-level organizations will be transferred from Research Division and Development Division into Sohyaku. Innovative Research Division.

4. Ikuyaku. Integrated Value Development Division (Effective October 1, 2015)

- The position of Deputy Division Manager to support the Division Manager will be newly established.
- Ikuyaku Product Strategy Department will be newly established. Part of the functions of Global Product Strategy Department will be transferred to Ikuyaku Product Strategy Department.
- Product Management Department and Product Coordination Department will be newly established.
- Product Marketing Department will be transferred from Sales & Marketing Division to Ikuyaku. Integrated Value Development Division.
- Medicinal Intelligence Department will be transferred from Corporate Division to Ikuyaku. Integrated Value Development Division.
- Medical Science Center, responsible for clarifying product profiles as well as maximizing product value, will be newly established. The functions of Medical Affairs Department of Corporate Division as well as Medical Information Center of Sales & Marketing Division will be transferred to Medical Science Center.
- Medical Affairs Department I and Medical Affairs Department II will be newly established directly under Medical Science Center, and the functions of Medical Affairs Department will be reorganized into the above departments. Furthermore, Ikuyaku Medical Research Department and Science Communication Office will be newly established.
- Pharmacovigilance Center, responsible for activities relating to safety information regarding drugs in development and marketed products, will be newly established. Pharmacovigilance Coordination & Administration Department, Safety Information Department, and Pharmacovigilance Department will be transferred from Pharmacovigilance & Quality Assurance Division to come directly under Pharmacovigilance Center.
- Ikuyaku Regulatory Affairs Center will be newly established. Quality Audit Department and Marketed Drug Regulatory Affairs Department will be transferred from Pharmacovigilance & Quality Assurance Division to come directly under Ikuyaku Regulatory Affairs Center.
- PV & QA Planning and Coordination Department of Pharmacovigilance & Quality Assurance Division will be abolished.

5. Sales & Marketing Division (Effective October 1, 2015)

- Sales Human Resources Department will be newly established. Part of the functions of Strategic Sales Planning Department will be transferred to Sales Human Resources Department.
- Primary Product Marketing Department will be newly established. Cardiovascular & Allergology Product Marketing Department and Diabetes Product Marketing Department will be integrated into Primary Product Marketing Department.

6. Production Division (Effective October 1, 2015)

- Production Innovation Office will be newly established to promote efficiency of production and the SCM system.

End

For Details, Contact the Following Section
Corporate Communications Department
Tel +81-6-6205-5211 (Headquarters)
Tel +81-3-6748-7664 (Tokyo Head Office)

Mitsubishi Tanabe Pharma Corporation Organization Chart (Effective October 1, 2015)

